BIPOLAR I DISORDER

This study looked at the long-term safety of cariprazine in 310 children with schizophrenia, bipolar I disorder, or autism spectrum disorder over 52 weeks. The main goal was to track side effects and changes in health measures like lab tests, vital signs, and movement disorders. …

This study tested whether a new drug, VHX-896, works like the existing drug iloperidone in 26 adults with schizophrenia or bipolar I disorder. Participants took both drugs in a crossover design to compare how the body processes them. The goal was to check if VHX-896 is a safe and…

This study looked at whether repeated ketamine infusions can help people with bipolar depression who did not get better with other treatments. 41 adults who already responded to an initial course of ketamine received up to 6 more infusions over 12 weeks. The goal was to see if th…

This early-stage study tested the safety and tolerability of the drug MK-8189 (elpipodect) in 34 adults with stable bipolar I disorder. Participants were in a non-acute phase of their illness and had previously tolerated antipsychotic medication. The study did not test whether th…

This study tested whether repeated doses of intravenous ketamine can safely and effectively reduce depression in people with bipolar disorder who haven't responded to other treatments. 71 adults with bipolar I or II and current major depression received four ketamine infusions or…

This study followed 120 adults with bipolar I disorder who were starting cariprazine (Vraylar) for a major depressive episode. Researchers measured changes in depression symptoms, daily functioning, and quality of life over 24 weeks in real-world clinic settings. The goal was to …

This study tested an experimental drug called ABBV-932 in 161 adults with bipolar I or II disorder who were currently experiencing a depressive episode. Participants took either the drug or a placebo daily for 6 weeks to see if it safely improves mood and reduces depression sympt…

This study tested an investigational medication called BXCL501 for calming agitation episodes in people with bipolar disorder, schizophrenia, or related conditions. 452 participants received either the drug or a placebo, and researchers measured changes in agitation levels and sa…

This study looked at whether voice and speech patterns change during manic episodes in people with Bipolar I Disorder. Researchers analyzed audio recordings from 17 hospitalized participants for pitch, rhythm, grammar, and word use. The goal was to find objective markers that cou…

This study looked at whether a program called NAVIGATE helps youth (ages 14-35) having their first episode of psychosis get better coordinated care. Researchers worked with 100 participants across Ontario to see if the program reduces hospital stays and ER visits. The goal was to…

This study looked at whether family members or caregivers can help measure agitation in people with bipolar disorder or schizophrenia. 33 adults took a single dose of an experimental medicine, and researchers compared ratings from doctors, patients, and their family members. The …